$HYPR
Hyperfine, Inc.

2022 Q2 Form 10-Q Financial Statement

#000095017022016936 Filed on August 11, 2022

View on sec.gov

Income Statement

Concept 2022 Q2 2022 Q1 2021 Q4
Revenue $1.533M $1.509M
YoY Change 328.21% 355.89%
Cost Of Revenue $1.698M $1.425M
YoY Change 271.55% 134.38%
Gross Profit -$165.0K $84.00K
YoY Change 66.67% -130.32%
Gross Profit Margin -10.76% 5.57%
Selling, General & Admin $15.76M $15.52M
YoY Change 86.53% 408.22%
% of Gross Profit 18477.38%
Research & Development $7.265M $8.334M
YoY Change 20.34% 86.28%
% of Gross Profit 9921.43%
Depreciation & Amortization $263.0K $253.0K
YoY Change 115.57% 163.54%
% of Gross Profit 301.19%
Operating Expenses $23.03M $23.86M
YoY Change 58.95% 216.88%
Operating Profit -$23.19M -$23.77M
YoY Change 59.0% 204.56%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $1.000K -$5.000K
YoY Change 0.0% -183.33%
Pretax Income -$23.16M -$23.78M
YoY Change 58.84% 205.04%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$23.16M -$23.78M
YoY Change 58.84% 205.04%
Net Earnings / Revenue -1510.7% -1575.55%
Basic Earnings Per Share -$0.33 -$0.34
Diluted Earnings Per Share -$0.33 -$0.34
COMMON SHARES
Basic Shares Outstanding 70.35M 70.33M
Diluted Shares Outstanding 70.35M 70.33M

Balance Sheet

Concept 2022 Q2 2022 Q1 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $145.1M $161.6M $188.5M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory $4.646M $4.538M $4.310M
Prepaid Expenses
Receivables $1.987M $1.944M $553.0K
Other Receivables
Total Short-Term Assets $157.0M $173.7M $197.5M
YoY Change 12571.87% 11910.13% 189.0%
LONG-TERM ASSETS
Property, Plant & Equipment $3.498M $3.877M $3.753M
YoY Change 97.11%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.179M $1.222M $1.235M
YoY Change 2706.82%
Total Long-Term Assets $4.677M $5.099M $4.988M
YoY Change -97.74% -97.54% 56.27%
TOTAL ASSETS
Total Short-Term Assets $157.0M $173.7M $197.5M
Total Long-Term Assets $4.677M $5.099M $4.988M
Total Assets $161.7M $178.8M $202.5M
YoY Change -22.35% -14.21% 183.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.697M $1.745M $2.248M
YoY Change 137.13%
Accrued Expenses
YoY Change
Deferred Revenue $964.0K $973.0K $730.0K
YoY Change 362.03%
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $10.46M $11.41M $15.74M
YoY Change 670.1% 9132.54% 282.31%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $10.46M $11.41M $15.74M
Total Long-Term Liabilities
Total Liabilities $11.20M $12.27M $16.25M
YoY Change 30.19% 66.45% 278.34%
SHAREHOLDERS EQUITY
Retained Earnings -$183.3M -$160.1M -$136.3M
YoY Change 2392.52% 2605.11% 90.74%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $150.5M $166.6M $186.2M
YoY Change
Total Liabilities & Shareholders Equity $161.7M $178.8M $202.5M
YoY Change -22.35% -14.21% 183.08%

Cashflow Statement

Concept 2022 Q2 2022 Q1 2021 Q4
OPERATING ACTIVITIES
Net Income -$23.16M -$23.78M
YoY Change 58.84% 205.04%
Depreciation, Depletion And Amortization $263.0K $253.0K
YoY Change 115.57% 163.54%
Cash From Operating Activities -$27.29M
YoY Change 264.53%
INVESTING ACTIVITIES
Capital Expenditures $308.0K
YoY Change 81.18%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$308.0K
YoY Change 81.18%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities -27.29M
Cash From Investing Activities -308.0K
Cash From Financing Activities
Net Change In Cash -27.60M
YoY Change -3279.37%
FREE CASH FLOW
Cash From Operating Activities -$27.29M
Capital Expenditures $308.0K
Free Cash Flow -$27.60M
YoY Change 260.46%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
CY2022Q2 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001833769
CY2022Q2 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39949
dei Entity Registrant Name
EntityRegistrantName
Hyperfine, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1569027
dei Entity Address Address Line1
EntityAddressAddressLine1
351 New Whitfield Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Guilford
dei Entity Address State Or Province
EntityAddressStateOrProvince
CT
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
06437
dei City Area Code
CityAreaCode
866
dei Local Phone Number
LocalPhoneNumber
-6767
dei Security12b Title
Security12bTitle
Class A common stock, $0.0001 Par Value Per Share
dei Trading Symbol
TradingSymbol
HYPR
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2021Q2 hypr Fairvalueassetlevel1 Tolevel2 Transfersamount
Fairvalueassetlevel1Tolevel2Transfersamount
0
CY2021Q2 hypr Fairvalueassetlevel2 Tolevel1 Transfersamount
Fairvalueassetlevel2Tolevel1Transfersamount
0
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
145104000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
188498000
CY2022Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
1604000
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
2662000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15736000
CY2022Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
745000
CY2022Q2 hypr Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
6109000
CY2021Q4 hypr Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
8115000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
10455000
CY2022Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
151000
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
32000
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1987000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
553000
CY2022Q2 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
1118000
CY2021Q4 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
91000
CY2022Q2 us-gaap Inventory Net
InventoryNet
4646000
CY2021Q4 us-gaap Inventory Net
InventoryNet
4310000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2570000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1357000
CY2022Q2 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
2000
CY2021Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
14000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
157031000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
197485000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3498000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3753000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1179000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1235000
CY2022Q2 us-gaap Assets
Assets
161708000
CY2021Q4 us-gaap Assets
Assets
202473000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1697000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2248000
CY2022Q2 hypr Deferred Grant Funding Current
DeferredGrantFundingCurrent
1604000
CY2021Q4 hypr Deferred Grant Funding Current
DeferredGrantFundingCurrent
2662000
CY2022Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
964000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
730000
CY2022Q2 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
81000
CY2021Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
1981000
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
510000
CY2022Q2 us-gaap Liabilities
Liabilities
11200000
CY2021Q4 us-gaap Liabilities
Liabilities
16246000
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
333755000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
322540000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-183254000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-136320000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
150508000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
186227000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
161708000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
202473000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1533000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
358000
us-gaap Operating Income Loss
OperatingIncomeLoss
-46963000
us-gaap Operating Income Loss
OperatingIncomeLoss
-22391000
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
32000
CY2021Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
5000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3042000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
689000
us-gaap Investment Income Interest
InvestmentIncomeInterest
33000
us-gaap Investment Income Interest
InvestmentIncomeInterest
10000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1000
CY2022Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1698000
CY2021Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
457000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3123000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1065000
CY2022Q2 us-gaap Gross Profit
GrossProfit
-165000
CY2021Q2 us-gaap Gross Profit
GrossProfit
-99000
us-gaap Gross Profit
GrossProfit
-81000
us-gaap Gross Profit
GrossProfit
-376000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7265000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6037000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15599000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10511000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12012000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6663000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
23372000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8521000
CY2022Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3750000
CY2021Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1787000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
7911000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2983000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
23027000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
14487000
us-gaap Operating Expenses
OperatingExpenses
46882000
us-gaap Operating Expenses
OperatingExpenses
22015000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-23192000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-14586000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
7000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-23159000
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-14580000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-46934000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-22374000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-23159000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-14580000
us-gaap Net Income Loss
NetIncomeLoss
-46934000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-67832000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-14580000
CY2021Q2 hypr Adjustments To Additional Paid In Capital Investments
AdjustmentsToAdditionalPaidInCapitalInvestments
2816000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1434000
us-gaap Net Income Loss
NetIncomeLoss
-22374000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.33
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.33
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-8.80
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-8.80
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.67
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.67
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-13.72
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-13.72
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
70350178
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
70350178
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1657345
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1657345
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
70341411
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
70341411
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1630190
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1630190
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
186227000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-23775000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4111000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
166563000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-23159000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7102000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
150508000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-61054000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-7794000
CY2021Q1 hypr Adjustments To Additional Paid In Capital Investments
AdjustmentsToAdditionalPaidInCapitalInvestments
700000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
49000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
267000
CY2021Q2 hypr Conversion Of Liminal Common Stock
ConversionOfLiminalCommonStock
-9350000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
149000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1489000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-87308000
us-gaap Profit Loss
ProfitLoss
-46934000
us-gaap Profit Loss
ProfitLoss
-22374000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
516000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
218000
us-gaap Share Based Compensation
ShareBasedCompensation
11213000
us-gaap Share Based Compensation
ShareBasedCompensation
1756000
us-gaap Inventory Write Down
InventoryWriteDown
0
us-gaap Inventory Write Down
InventoryWriteDown
33000
us-gaap Net Investment In Lease Purchase
NetInvestmentInLeasePurchase
4000
us-gaap Net Investment In Lease Purchase
NetInvestmentInLeasePurchase
5000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
263000
hypr Unbilled Receivables
UnbilledReceivables
1027000
hypr Unbilled Receivables
UnbilledReceivables
39000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
336000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
449000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1213000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
357000
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
-12000
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
-1279000
us-gaap Increase Decrease Due From Other Related Parties
IncreaseDecreaseDueFromOtherRelatedParties
193000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-52000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
20000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-551000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
196000
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-1058000
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-322000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
469000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
554000
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-1900000
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-50000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-2013000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
536000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-44200000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19104000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
254000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
675000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-254000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-675000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
198000
us-gaap Proceeds From Issuance Of Redeemable Preferred Stock
ProceedsFromIssuanceOfRedeemablePreferredStock
30468000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
7000
us-gaap Proceeds From Contributions From Affiliates
ProceedsFromContributionsFromAffiliates
3516000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
34175000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-44452000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
14396000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
191160000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
64286000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
146708000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
78682000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
145104000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
77394000
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1604000
CY2021Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1288000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
146708000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
78682000
hypr Cash Received From Exchange Of Research And Development Tax Credits
CashReceivedFromExchangeOfResearchAndDevelopmentTaxCredits
324000
hypr Write Off Of Notes Receivable
WriteOffOfNotesReceivable
90000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the condensed combined and consolidated financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions about future events that affect the amounts reported in its condensed combined and consolidated financial statements and accompanying notes. Future events and their effects cannot be determined with certainty. On an ongoing basis, management evaluates these estimates and assumptions. Significant estimates and assumptions included:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span> </p><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Revenue recognition, including determination of the timing and pattern of satisfaction of performance obligations, determination of the standalone selling price (“SSP”) of performance obligations and estimation of variable consideration;</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Allowance for doubtful accounts;</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Net realizable value (the selling price as well as estimated costs of disposal and transportation) of inventory, and demand and future use of inventory;</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Valuation allowances with respect to deferred tax assets; and</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Assumptions underlying the fair value used in calculation of the stock-based compensation expense.</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span> </p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company bases these estimates on historical and anticipated results and trends and on various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates, and any such differences may be material to the Company’s condensed </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">combined and consolidated financial statements. </span>
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1533000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
358000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3042000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
689000
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1987000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
553000
CY2022Q2 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
1118000
CY2021Q4 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
91000
CY2022Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
964000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
730000
CY2022Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
745000
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
510000
hypr Revenue Recognize Receivable Payment Terms Range Minimum
RevenueRecognizeReceivablePaymentTermsRangeMinimum
P20D
hypr Revenue Recognize Receivable Payment Terms Range Maximum
RevenueRecognizeReceivablePaymentTermsRangeMaximum
P6M
CY2022Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
180000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
383000
CY2021Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
56000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
114000
CY2022Q2 us-gaap Capitalized Contract Cost Net
CapitalizedContractCostNet
210000
CY2021Q4 us-gaap Capitalized Contract Cost Net
CapitalizedContractCostNet
158000
CY2022Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
3924000
CY2021Q4 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
2800000
CY2022Q2 hypr Revenue Remaining Performance Obligation Expected Timing Percentage
RevenueRemainingPerformanceObligationExpectedTimingPercentage
0.22
CY2022Q2 hypr Revenue Remaining Performance Obligation Expected Timing Percentage
RevenueRemainingPerformanceObligationExpectedTimingPercentage
0.78
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1896000
CY2022Q2 hypr Fairvalueassetlevel1 Tolevel2 Transfersamount
Fairvalueassetlevel1Tolevel2Transfersamount
0
CY2022Q2 hypr Fairvalueassetlevel2 Tolevel1 Transfersamount
Fairvalueassetlevel2Tolevel1Transfersamount
0
CY2022Q2 hypr Fairvalueliabilitylevel1 Tolevel2 Transfersamount
Fairvalueliabilitylevel1Tolevel2Transfersamount
0
CY2022Q2 hypr Fairvalueliabilitylevel2 Tolevel1 Transfersamount
Fairvalueliabilitylevel2Tolevel1Transfersamount
0
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1630190
CY2021Q2 hypr Fairvalueliabilitylevel1 Tolevel2 Transfersamount
Fairvalueliabilitylevel1Tolevel2Transfersamount
0
CY2021Q2 hypr Fairvalueliabilitylevel2 Tolevel1 Transfersamount
Fairvalueliabilitylevel2Tolevel1Transfersamount
0
CY2022Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
2366000
CY2021Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
2355000
CY2022Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
2280000
CY2021Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1955000
CY2022Q2 us-gaap Inventory Net
InventoryNet
4646000
CY2021Q4 us-gaap Inventory Net
InventoryNet
4310000
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5394000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5163000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1410000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3498000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3753000
CY2022Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
263000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
516000
CY2021Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
122000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
218000
CY2022Q2 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
2986000
CY2021Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
3421000
CY2022Q2 hypr Accrued Contracted Services Current
AccruedContractedServicesCurrent
857000
CY2021Q4 hypr Accrued Contracted Services Current
AccruedContractedServicesCurrent
2711000
CY2021Q4 hypr Accrued Bonus And Other Costs Current
AccruedBonusAndOtherCostsCurrent
1071000
CY2022Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
170000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
452000
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2031000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
441000
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
65000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
19000
CY2022Q2 hypr Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
6109000
CY2021Q4 hypr Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
8115000
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
70350178
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1657345
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1657345
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
70341411
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
70341411
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1630190
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7522136
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4231693
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
271368
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11482461
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
699170
CY2022Q2 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
16375
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
383090
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11782166
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7102000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1489000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11213000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1756000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-23159000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-14580000
us-gaap Net Income Loss
NetIncomeLoss
-46934000
us-gaap Net Income Loss
NetIncomeLoss
-22374000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-23159000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14580000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-46934000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-22374000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
70350178
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.33
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.33
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-8.80
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-8.80
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.67
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.67
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-13.72
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-13.72
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
24148716
CY2021Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
54511052
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
24148716
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
54511052
CY2022Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2021Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2018Q1 us-gaap Due From Employees Noncurrent
DueFromEmployeesNoncurrent
90000
CY2018Q1 us-gaap Related Party Transaction Rate
RelatedPartyTransactionRate
0.0168
CY2022Q1 hypr Due From Employees Forgiveness
DueFromEmployeesForgiveness
90000
CY2020Q4 hypr Deferred Grant Funding Current
DeferredGrantFundingCurrent
1610000
CY2020 hypr Number Of Sites
NumberOfSites
20
CY2021 hypr Grant Awarded
GrantAwarded
3300000
CY2021 hypr Grant Awarded For Provision And Equipping
GrantAwardedForProvisionAndEquipping
2500000
CY2021 hypr Number Of Sites
NumberOfSites
5
hypr Grant Awarded For Provision And Equipping
GrantAwardedForProvisionAndEquipping
800000
CY2022Q2 hypr Deferred Grant Funding Current
DeferredGrantFundingCurrent
1604000
CY2021Q4 hypr Deferred Grant Funding Current
DeferredGrantFundingCurrent
2662000
CY2022Q2 hypr Grant Fund Required To Return Under Provisions
GrantFundRequiredToReturnUnderProvisions
0
CY2021Q4 hypr Grant Fund Required To Return Under Provisions
GrantFundRequiredToReturnUnderProvisions
0
CY2021 us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
1000000
CY2022Q2 hypr Earn Out Liability
EarnOutLiability
0

Files In Submission

Name View Source Status
0000950170-22-016936-index-headers.html Edgar Link pending
0000950170-22-016936-index.html Edgar Link pending
0000950170-22-016936.txt Edgar Link pending
0000950170-22-016936-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
hypr-20220630.htm Edgar Link pending
hypr-20220630.xsd Edgar Link pending
hypr-ex10_1.htm Edgar Link pending
hypr-ex31_1.htm Edgar Link pending
hypr-ex31_2.htm Edgar Link pending
hypr-ex32.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
hypr-20220630_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
hypr-20220630_pre.xml Edgar Link unprocessable
hypr-20220630_lab.xml Edgar Link unprocessable
hypr-20220630_htm.xml Edgar Link completed
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
hypr-20220630_cal.xml Edgar Link unprocessable